ArticleTranslational cancer research2026
Association between pan-immune-inflammation value and prognosis in lung cancer patients: a systematic review and meta-analysis.
Article in Translational cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The prognostic role of pan-immune-inflammation value (PIV) in lung cancer remains unclear. This meta-analysis aimed to identify the relationship between PIV and prognosis in lung cancer. Methods: Several databases were searched up to April 26, 2025. Endpoints included the overall survival (OS), progression-free survival (PFS), objective response rate (ORR), disease control rate (DCR), complete response rate (CRR), and pulmonary infection (PI). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were combined. Subgroup analysis by tumor type and treatment for OS and PFS was performed. Results: Eighteen studies involving 4,367 cases were included. Our results indicated that a high PIV was associated with poor OS (HR =2.38; 95% CI: 2.06-2.75; P<0.001) and PFS (HR =1.93; 95% CI: 1.67-2.23; P<0.001). Subgroup analysis by tumor type and treatment further identified the above findings. Furthermore, PIV was also related to the ORR (OR =0.56; 95% CI: 0.39-0.80; P=0.002), DCR (OR =0.61; 95% CI: 0.43-0.88; P=0.007), CRR (OR =0.42; 95% CI: 0.19-0.92; P=0.03), and risk of PI (OR =2.15; 95% CI: 1.02-4.51; P=0.044). Conclusions: PIV may serve as a prognostic biomarker associated with survival outcomes in lung cancer, and patients with a high PIV tend to have a worse prognosis. However, PIV should be interpreted as a surrogate marker reflecting systemic inflammatory status rather than a causal determinant of disease progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.